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Abstract A complication is an event or occurrence that is associated with a disease or a healthcare
intervention, is a departure from the desired course of events, and may cause, or be associated with, suboptimal
outcome. A complication does not necessarily represent a breech in the standard of care that constitutes
medical negligence or medical malpractice. An operative or procedural complication is any complication,
regardless of cause, occurring (1) within 30 days after surgery or intervention in or out of the hospital, or
(2) after 30 days during the same hospitalization subsequent to the operation or intervention. Operative and
procedural complications include both intraoperative/intraprocedural complications and postoperative/
postprocedural complications in this time interval.
The MultiSocietal Database Committee for Pediatric and Congenital Heart Disease has set forth a
comprehensive list of complications associated with the treatment of patients with congenital cardiac disease,
related to cardiac, pulmonary, renal, haematological, infectious, neurological, gastrointestinal, and endocrinal
systems, as well as those related to the management of anaesthesia and perfusion, and the transplantation of
thoracic organs. The objective of this manuscript is to examine the definitions of operative morbidity as they
relate specifically to the haematological system and to infectious complications. These specific definitions and
terms will be used to track morbidity associated with surgical and transcatheter interventions and other forms
of therapy in a common language across many separate databases.
The MultiSocietal Database Committee for Pediatric and Congenital Heart Disease has prepared and
defined a near-exhaustive list of haematological and infectious complications. Within each subgroup,
complications are presented in alphabetical order. Clinicians caring for patients with congenital cardiac disease
will be able to use this list for databases, quality improvement initiatives, reporting of complications, and
comparing strategies for treatment.
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T
HROUGH THE WORK OF A VARIETY OF INDIVIDUALS,
societies, and organizations, the reporting and
analyzing of outcomes related to the treatments
of patients with congenitally malformed hearts has
increased substantially.1–4 These ongoing efforts have
yielded a fundamental expectation of providing
performance metrics that will be utilized by patients,
providers, and payers. The value of these metrics relies
upon a quantifiable standard for quality of care.
Efforts to date have concentrated on global measures
of outcomes, such as mortality,3 length of stay,5 or
utilization of resources. While these measures are
important, it is recognized that need exists to develop
better measurement parameters of performance, as
well as accurate and universally accepted measures of
morbidity associated with surgery for congenital
cardiac disease. Prior to defining quality of care, a
universal nomenclature must be developed that
defines the complications associated with the treat-
ment of patients with congenital cardiac disease. It is
necessary to develop the tools to allow for the careful
analysis of not only the success associated with
surgical performance, but also of complications. These
complications must be assessed and documented in a
reproducible and measurable fashion.
A working group representing the MultiSocietal
Database Committee for Pediatric and Congenital
Heart Disease was convened to approach analysis
of organ based complications. This group undertook
the evaluation of complications associated with the
treatment of patients with congenital cardiac disease,
related to cardiac, pulmonary, renal, haematological,
infectious, neurological, gastrointestinal, and endocrinal
systems, as well as those related to the management
of anaesthesia and perfusion, and the transplantation
of thoracic organs. The Societies and organizations
represented in the MultiSocietal Database Committee
for Pediatric and Congenital Heart Disease are
presented in the Introduction to this Supplement.
The objective of this manuscript is to examine the
definitions of operative complications as they relate
specifically to the haematologic system and to
infectious complications. Specific definitions and
terms, adjudicated by consensus, could serve as a
common language, which could be used to track
rates of morbidity associated with surgical inter-
vention across databases.
Historical background
Previous attempts at describing and monitoring
haematological and infectious complications have
been limited to descriptive presentations by indi-
vidual centres or by individual countries.6–10 To
date, however, the descriptions have not been
standardized, neither with regards to nomenclature,
nor to their definition or analysis. This shortcoming
has led to wide variability in the haematological
complication rates associated with cardiac surgery,
with published rates ranging from 0.03% to 3.5%, a
more than ten-fold difference. This variation in
reported complication rate can be explained in part
by the fact that some groups include only haemor-
rhagic complications as haematological complications,
others have concentrated on thromboembolic compli-
cations, and yet others have included the complica-
tions associated with any use of blood components.
This discrepancy has led to incomplete representation
of risk and benefit associated with treatment, thus
resulting in confusing and conflicting data.
Consensus definitions
In Part 4 of this Supplement, within each organ system,
complications are presented and defined in alphabetical
order. The process for creating this list of complications
began in 1998 with initiation of the International
Congenital Heart Surgery Nomenclature and Database
Project of The Society of Thoracic Surgeons and
The European Association for Cardiothoracic Surgery.11
In April of 2000, common database standards for
congenital heart surgery were published and incorpo-
rated into the databases of The Society of Thoracic
Surgeons and The European Association for Cardiotho-
racic Surgery. This effort was followed in 2005 by the
formation of MultiSocietal Database Committee for
Pediatric and Congenital Heart Disease and its Risk
Factor and Complications Subcommittee, with the task
of reaching clear, specific and universally acceptable
definitions of risk factors and complications.
The Congenital Heart Surgery Databases of The
Society of Thoracic Surgeons and The European
Association for Cardiothoracic Surgery have used
a common Complications Short List since 2000.
A need existed to agree upon a comprehensive
Complications Long List. Starting with the Com-
plications List of The Society of Thoracic Surgeons
and The European Association for Cardiothoracic
Surgery, a draft of a more complete Complications
Long List was created, with further breakdown within
this list as to which complications are specific for the
intra-operative time frame. This work was initially
presented at a meeting of The Society of Thoracic
Surgeons Congenital Database Taskforce in 2006.
The next steps of the group were to create a
Complications Long List acceptable to all of the
members of MultiSocietal Database Committee for
Pediatric and Congenital Heart Disease. This
Complications Long List would then become part
of the International Pediatric and Congenital
Cardiac Code (IPCCC). This Complications Long
List would be mapped to a more manageable
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Complications Short Lists that can be used in multi-
institutional databases. The project was organized by
dividing the Complications Long List by organ
systems. Subcommittees were created for each organ
system, with representatives included from each of the
societies and groups in the MultiSocietal Database
Committee for Pediatric and Congenital Heart
Disease. The authors of this manuscript represent
the subgroup that was tasked with defining haema-
tological and infectious complications.
Each subcommittee evaluated the Long Lists and
Short Lists of the various member Societies and
proposed definitions for all of the terms in each list.
Particular emphasis was placed on the following
two Long Lists and Short Lists:
> The International Congenital Heart Surgery
Nomenclature and Database Project11 of The
Society of Thoracic Surgeons and The European
Association for Cardiothoracic Surgery
> The European Paediatric Cardiac Code of The
Association for European Pediatric Cardiology.12
Experts in a particular organ system were
consulted for assistance in definition development
at the discretion of the individual subcommittees.
These definitions were then circulated to all
participants. Finally, a summit was held to discuss
and finalize all definitions. These adjudicated
definitions will be used in the multiple databases
of various member Societies that compose the
MultiSocietal Database Committee for Pediatric
and Congenital Heart Disease and the terminology
will be incorporated into the International Pediatric
and Congenital Cardiac Code [www.ipccc.net]. The
original working list of hematologic and infectious
complications is found in Table 1 of this manu-
script. The terms in Table 1 served as the starting
point and were fused with complementary terms
from several other lists including The European
Paediatric Cardiac Code.12 Table 2 lists the terms in
the final list of haematologic and infectious
complications. These terms in the final list are all
also listed in Part 4 of this Supplement with their
official definitions.
Infections involving vascular lines, or ‘‘line
infections’’, and infections involving wounds, or
‘‘wound infections’’ are discussed in detail in the
manuscript in this Supplement titled ‘‘Integument,
Vascular, Vascular-Line(s), and Wound Complica-
tions associated with Congenital Cardiac Surgery:
Consensus Definitions from the Multi-Societal
Database Committee for Pediatric and Congenital
Heart Disease’’. In Part 4 of this Supplement, these
infectious complications are then listed and defined
under the system headings of ‘‘Vascular-Line(s)’’ and
‘‘Wound’’ respectively.
Infections involving the lungs, such as pneumonia,
are discussed in detail in the manuscript in this
Supplement titled ‘‘Pulmonary Complications’’. In
Part 4 of this Supplement, these infectious pulmonary
complications are then listed and defined under the
system heading of ‘‘Pulmonary’’.
Also in Part 4 of this Supplement, Endocarditis is
listed and defined under the system heading of
‘‘Cardiac’’.
Controversies
Overall, working group consensus was achieved for
most of the list of the haematological and infectious
complications. The major source of controversy centred
on defining the time course for each complication.
This was felt to be important since some agents, such
as protamine, will elicit a near-immediate reaction,
Table 1. The Initial List of Haematologic and Infectious
Complications.
Haematologic complications
1. Anticoagulant complication
2. Anticoagulant complication, Secondary to intraoperative heparin
3. Other
4. Protamine reaction
5. Reaction to antifibrinolytic drug
6. Reaction to aprotinin
7. Reaction to blood products
8. Reaction to blood products, Reaction to packed red blood cells
9. Reaction to blood products, Reaction to plasma
10. Reaction to blood products, Reaction to platelets
Infectious complications
1. Endocarditis
2. Endocarditis, Bacterial
3. Endocarditis, Fungal
4. Infection, Multiple
5. Mediastinitis
6. Other
7. Pneumonia
8. Sepsis
9. Sepsis Staph epi, In blood
10. Sepsis, Enterobacter, In blood
11. Sepsis, Multi-system Organ Failure
12. Sepsis, Pseudomonas, In blood
13. Sepsis, Septic shock
14. Sepsis, Staph aureus – MRSA, In blood
15. Sepsis, Staph aureus – non-MRSA, In blood
16. Sepsis, Staph aureus, In blood
17. Sepsis, Yeast, In blood
18. UTI
19. UTI, Bacterial
20. UTI, Bacterial, Pseudomonas
21. UTI, Yeast
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Table 2. The Final List of Haematologic and Infectious Complications.
Precise definitions for these complications are given in Part 4 of the Supplement
Haematologic complications
1. Anaphylactic or anaphylactoid reaction to antifibrinolytic drug
2. Anaphylactic or anaphylactoid reaction to antifibrinolytic drug, Reaction to tranexamic acid
3. Anaphylactic or anaphylactoid reaction to antifibrinolytic drug, Reaction to aminocaproic acid
4. Anaphylactic or anaphylactoid reaction to antifibrinolytic drug, Reaction to aprotinin
5. Anticoagulant complication
6. Anticoagulant complication, Difficulty in achieving adequate anticoagulation
7. Anticoagulant complication, Hemorrhagic
8. Anticoagulant complication, Heparin Induced Thrombocytopenia (HIT)
9. Anticoagulant complication, Prothrombotic
10. Anticoagulant complication, Secondary to intraoperative/intraprocedural heparin
11. Cold agglutinin reaction
12. Hematologic complication
13. Protamine reaction
14. Protamine reaction, Biochemically confirmed
15. Protamine reaction, Clinically suspected
16. Prothrombotic and/or hemorrhagic reaction to antifibrinolytic drug
17. Prothrombotic and/or hemorrhagic reaction to antifibrinolytic drug, Reaction to tranexamic acid
18. Prothrombotic and/or hemorrhagic reaction to antifibrinolytic drug, Reaction to aminocaproic acid
19. Prothrombotic and/or hemorrhagic reaction to antifibrinolytic drug, Reaction to aprotinin
20. Reaction to blood products
21. Reaction to blood products, Post-transplant graft versus host disease
22. Reaction to blood products, Reaction to cryoprecipitate
23. Reaction to blood products, Reaction to packed red blood cells
24. Reaction to blood products, Reaction to plasma
25. Reaction to blood products, Reaction to platelets
26. Reaction to blood products-modifier
27. Reaction to blood products-modifier, ABO mismatch transfused
28. Reaction to blood products-modifier, Administration of wrong blood product
29. Reaction to blood products-modifier, Error from improperly identifying patient
30. Reaction to blood products-modifier, Major
31. Reaction to blood products-modifier, Minor
32. Sickle cell crisis
Infectious complications
Please note the following:
> Endocarditis is listed and defined under the system heading of ‘‘Cardiac’’.
> Infections involving the lungs, such as pneumonia, are listed and defined under the system heading of ‘‘Pulmonary’’.
> Infections involving vascular lines, or ‘‘line infections’’, and infections involving wounds, or ‘‘wound infections’’ are listed and defined
under the system headings of ‘‘Vascular-Line(s)’’ and ‘‘Wound’’ respectively.
1. Infection
2. Infection, Multiple
3. Infection-modifier for causative organism
4. Infection-modifier for causative organism, Bacterial
5. Infection-modifier for causative organism, Bacterial, Enterobacter
6. Infection-modifier for causative organism, Bacterial, Enterococcus
7. Infection-modifier for causative organism, Bacterial, Enterococcus (Vancomycin-resistant enterococci [VRE])
8. Infection-modifier for causative organism, Bacterial, Etiology unknown
9. Infection-modifier for causative organism, Bacterial, Etiology unspecified
10. Infection-modifier for causative organism, Bacterial, Gonococcal
11. Infection-modifier for causative organism, Bacterial, Haemophilus
12. Infection-modifier for causative organism, Bacterial, Klebsiella
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Table 2. Continued
13. Infection-modifier for causative organism, Bacterial, Meningococcal
14. Infection-modifier for causative organism, Bacterial, Pneumococcal
15. Infection-modifier for causative organism, Bacterial, Pseudomonas
16. Infection-modifier for causative organism, Bacterial, Pseudomonas aeruginosa
17. Infection-modifier for causative organism, Bacterial, Spirochetal
18. Infection-modifier for causative organism, Bacterial, Staphylococcal
19. Infection-modifier for causative organism, Bacterial, Staphylococcal, Staphylococcus aureus
20. Infection-modifier for causative organism, Bacterial, Staphylococcal, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus
(MRSA) negative
21. Infection-modifier for causative organism, Bacterial, Staphylococcal, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus
(MRSA) positive
22. Infection-modifier for causative organism, Bacterial, Staphylococcal, Staphylococcus epidermidis
23. Infection-modifier for causative organism, Bacterial, Streptococcal
24. Infection-modifier for causative organism, Bacterial, Syphilitic
25. Infection-modifier for causative organism, Bacterial, Tuberculous
26. Infection-modifier for causative organism, Bacterial, Typhoid
27. Infection-modifier for causative organism, Chlamydial
28. Infection-modifier for causative organism, Etiology unknown
29. Infection-modifier for causative organism, Etiology unspecified
30. Infection-modifier for causative organism, Fungal
31. Infection-modifier for causative organism, Fungal, Aspergillosis
32. Infection-modifier for causative organism, Fungal, Candidal
33. Infection-modifier for causative organism, Fungal, Yeast
34. Infection-modifier for causative organism, Non-bacterial infection
35. Infection-modifier for causative organism, Parasitic
36. Infection-modifier for causative organism, Protozoal (not Chagas’)
37. Infection-modifier for causative organism, Rickettsial
38. Infection-modifier for causative organism, Toxoplasmosis
39. Infection-modifier for causative organism, Trypanosomal (Chagas’ disease)
40. Infection-modifier for causative organism, Viral
41. Infection-modifier for causative organism, Viral, Adenovirus
42. Infection-modifier for causative organism, Viral, Coxsackie virus
43. Infection-modifier for causative organism, Viral, Cytomegalovirus (CMV)
44. Infection-modifier for causative organism, Viral, Echovirus
45. Infection-modifier for causative organism, Viral, Epstein-Barr virus (EBV)
46. Infection-modifier for causative organism, Viral, HIV
47. Infection-modifier for causative organism, Viral, Influenza virus
48. Infection-modifier for causative organism, Viral, Mumps virus
49. Infection-modifier for causative organism, Viral, Rubella
50. Infectious complication
51. Sepsis
52. Sepsis, Multi-system Organ Failure
53. Sepsis, Septic shock
54. Sepsis, Urosepsis
55. Sepsis, With documented bacteremia
56. Sepsis, With documented bacteremia, With Enterobacter in blood
57. Sepsis, With documented bacteremia, With Pseudomonas in blood
58. Sepsis, With documented bacteremia, With Staphylococcus aureus – MRSA (Methicillin Resistant Staphylococcus Aureus) in blood
59. Sepsis, With documented bacteremia, With Staphylococcus aureus – non-MRSA (non-Methicillin Resistant Staphylococcus Aureus) in
blood
60. Sepsis, With documented bacteremia, With Staphylococcus aureus in blood
61. Sepsis, With documented bacteremia, With Staphylococcus epidermidis in blood
62. Sepsis, With documented fungemia
63. Sepsis, With documented fungemia, With yeast in blood
64. Sepsis, With documented viremia
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whereas others, such as warfarin or aspirin, may not
become manifest until a much later time. There was
also considerable discussion regarding the infectious
complications of sepsis, septic shock, and the
systemic inflammatory response syndrome (SIRS).
Finally, the timeliness of the popular terms
‘‘ventilator acquired pneumonia’’, commonly referred
to as ‘‘VAP’’, and ‘‘blood stream infection’’, commonly
termed ‘‘BSI’’, deserve special attention.
It was agreed that the time course of operative
and procedural complications, for both the haema-
tological and infectious systems, would be confined
to the period of data collection that begins at
‘‘Operating Room Entry Date and Time’’, as defined
in Part 4 of this Supplement and as previously
published,5 and ends when the following criteria
have been met:
> 30 days have passed since the original operation
or procedure
> the patient has been discharge from the hospital
as defined in Part 4 of this Supplement and as
previously published.5
In other words, an operative or procedural
complication is any complication, regardless of cause,
occurring (1) within 30 days after surgery or inter-
vention in or out of the hospital, or (2) after 30 days
during the same hospitalization subsequent to the
operation or intervention. Operative and procedural
complications include both intraoperative/intraproce-
dural complications and postoperative/postprocedural
complications in this time interval.
These rules specifically pertain to the diagnosis
of Heparin Induced Thrombocytopenia (HIT), in
which antibody formation usually occurs within
5–10 days postoperatively. Similarly, specific infec-
tious complications are also tracked within this
‘‘operative and procedural’’ time window. For
example, the following definition is provided for
‘‘Urinary tract infection (UTI)’’:
‘‘A urinary tract infection is an infection of the urinary
tract, as defined by positive urine culture or white blood
cells (WBCs) present on urinalysis. A urinary tract
infection that will be counted as an operative or
procedural complication must occur prior to hospital
discharge or after hospital discharge but within 30 days of
the procedure. (An operative or procedural complication is
any complication, regardless of cause, occurring (1) within
30 days after surgery or intervention in or out of the
hospital, or (2) after 30 days during the same hospitaliza-
tion subsequent to the operation or intervention. Operative
and procedural complications include both intraoperative/
intraprocedural complications and postoperative/postproce-
dural complications in this time interval.)’’
The definition of sepsis was discussed and debated
extensively:
‘‘Sepsis is defined as ‘‘evidence of serious infection
accompanied by a deleterious systemic response’’. In the
time period of the first 48 postoperative or postprocedural
hours, the diagnosis of sepsis requires the presence of a
Systemic Inflammatory Response Syndrome (SIRS) result-
ing from a proven infection (such as bacteremia, fungemia
or urinary tract infection). In the time period after the first
48 postoperative or postprocedural hours, sepsis may be
diagnosed by the presence of a SIRS resulting from
suspected or proven infection. During the first 48 hours, a
SIRS may result from the stress associated with surgery
and/or cardiopulmonary bypass. Thus, the clinical criteria
for sepsis during this time period should be more
stringent. A systemic inflammatory response syndrome
(SIRS) is present when at least two of the following criteria
are present: hypo- or hyperthermia (.38.5 or ,36.0),
tachycardia or bradycardia, tachypnea, leukocytosis or
leukopenia, and thrombocytopenia.’’
Pneumonia and ventilator acquired pneumonia
are discussed in detail in the manuscript in this
Supplement titled in the ‘‘Pulmonary Complica-
tions’’. Because of the timeliness of the topic of
ventilator acquired pneumonia, we will address this
issue in this manuscript as well.
No ‘‘gold-standard’’ definition exists for the
diagnosis of ‘‘ventilator acquired pneumonia’’,
commonly referred to as ‘‘VAP’’. The criteria used
to make the diagnosis are controversial. Below, we
present the two best published consensus statements
for current diagnosis and treatment of ventilator
acquired pneumonia.
Table 2. Continued
65. Sepsis, With primary blood stream infection (BSI)5 hospital acquired blood stream infection (BSI)
66. Sepsis, With primary blood stream infection (BSI)5hospital acquired blood stream infection (BSI), In a patient with a central venous catheter
67. Sepsis, With primary blood stream infection (BSI)5 hospital acquired blood stream infection (BSI), In a patient with an arterial catheter
68. Urinary tract infection (UTI)
69. Urinary tract infection (UTI), Bacterial
70. Urinary tract infection (UTI), Bacterial, Pseudomonas
71. Urinary tract infection (UTI), Yeast
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The first ventilator acquired pneumonia consen-
sus statement guides clinicians and is a product of
the American Thoracic Society and the Infectious
Disease Association of the America.13 In brief,
ventilator acquired pneumonia diagnostic criteria
are applied using a combination of ‘‘clinical’’ and
‘‘quantitative’’ strategies to guide therapy, based on
cultures of the lower respiratory tract. These criteria
include the occurrence of new and persistent
radiographic infiltrates (at least 72 hours) in con-
junction with two of three clinical criteria (fever,
leukocytosis, purulent secretions) and positive
cultures using a threshold greater than 10,000 colony
forming units per millilitre (if the patient is on
antibiotics longer than 24hours, a threshold of greater
than 1000 colony forming units per millilitre is used).
As an invasive approach, bronchoscopic sampling is
preferred, but not required, in keeping with the
consensus protocol. However, bronchoscopic sampling
may be difficult in children.
The second ventilator acquired pneumonia con-
sensus statement guides investigators and is a
product of the International Sepsis Forum.14 Taking
into account that final microbiological (culture)
data only become available after-the-fact, ventilator
acquired pneumonia is defined post-hoc for report-
ing purposes as falling into one of three categories:
> Microbiologically confirmed or definite: clini-
cally present with abnormal chest radiograph
and the isolation of a likely pulmonary pathogen,
or the isolation of a likely/possible pulmonary
pathogen in high concentration from a quanti-
tative lower respiratory tract sample, or positive
serology,
> Probable: clinically present with abnormal chest
radiograph but without microbiological or
serological confirmation, or
> Possible: abnormal chest radiograph of uncertain
cause, with low or moderate clinical suspicion of
pneumonia, but with microbiological or serolo-
gic criteria of definite or probable pneumonia.14
The advantage of this second definition of
ventilator acquired pneumonia is that it accurately
captures the uncertainty of the diagnosis ‘‘in the real
world’’, allowing one to separate out those cases that
are culture positive from those cases that have no
cultures available or are culture-negative. This
stratification improves the predicative models of
ventilator acquired pneumonia that we generate, as
those models can incorporate and account for
variance in attending practice and the clinical
certainty (or uncertainty) of the diagnosis of
ventilator acquired pneumonia.
Infections of intravascular lines, or ‘‘Line infec-
tions’’ are discussed in detail in the manuscript in
this Supplement titled ‘‘Integument, Vascular,
Vascular-Line(s), and Wound Complications asso-
ciated with Congenital Cardiac Surgery: Consensus
Definitions from the Multi-Societal Database Com-
mittee for Pediatric and Congenital Heart Disease’’.
Because of the timeliness of the topic of blood
stream infections, a brief comment is made in our
manuscript as well. Definitions from the Centers for
Disease Control and Prevention of the United States
of America were used for primary blood stream
infections in patients with central venous or arterial
catheters.15 A ‘‘primary blood stream infection’’ may
also be considered a ‘‘hospital-acquired blood stream
infection’’ and is defined as an infection that began
48 hours or more after hospital admission and was
due to pathogenic microorganisms in the blood that
were not present or incubating before hospital
admission.
Interaction with the cardiac system
Severe infection can cause haemodynamic instability
and shock. The following definition is proposed for
shock:
‘‘Shock is defined as ‘a state of inadequate tissue
perfusion’. A modern definition according to Simeone
states that shock is a ‘clinical condition characterized by
signs and symptoms which arise when the cardiac output
is insufficient to fill the arterial tree with blood under
sufficient pressure to provide organs and tissues with
adequate blood flow.’ A historic definition according to
Blalock in 1940 is that ‘Shock is a peripheral circulatory
failure, resulting from a discrepancy in the size of the
vascular bed and the volume of the intravascular fluid’.’’
Septic shock is ‘‘a state of inadequate tissue
perfusion caused by sepsis’’. Septic shock is therefore
defined as a condition which meets the criteria
of the previously listed definitions of both sepsis
and shock.
Conclusion
Effective monitoring practices of peri-operative mor-
bidity are dependant upon standardized definitions of
the complications themselves. The MultiSocietal
Database Committee for Pediatric and Congenital
Heart Disease has set forth a comprehensive list of
complications associated with the treatment of patients
with congenital cardiac disease, related to cardiac,
pulmonary, renal, haematological, infectious, neurolo-
gical, gastrointestinal, and endocrinal systems, as well
as those related to the management of anaesthesia and
perfusion, and the transplantation of thoracic organs.
The objective of this manuscript is to examine the
definitions of operative morbidity as they relate
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specifically to the haematological system and to
infectious complications. These specific definitions
and terms will be used to track morbidity associated
with surgical and transcatheter interventions and other
forms of therapy in a common language across many
separate databases.
The areas of haematological and infectious compli-
cations are important to the field of congenital cardiac
surgery, specifically due to the current emphasis on
limiting utilization of blood products and rates of
nosocomial infections.14 Infectious complications are a
leading cause of morbidity and mortality after cardiac
surgical interventions. Additionally, forthcoming
‘‘pay-for-performance’’ initiatives will potentially limit
renumeration to healthcare providers based on the
incidence of postoperative infectious complications.
The definitions of these complications will, therefore,
take on potentially greater significance over time.
Haematological complications associated with either a
pro- or anti-coagulated state lead to significant
morbidity and mortality in our population as well.16
Analysis of the data on these important post-operative
morbidities across databases and centres requires the
common nomenclature developed by the consensus of
this working group.
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